The serotonin 5-HT₆ receptor: a viable drug target for treating cognitive deficits in Alzheimer’s disease

References

• Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ178(5), 548–556 (2008).
   PubMed Web of Science ®Google Scholar
• Chertkow H, Massoud F, Nasreddine Z et al. Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ178(10), 1273–1285 (2008).
   PubMed Web of Science ®Google Scholar
• Hogan DB, Bailey P, Black S et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ179(8), 787–793 (2008).
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Beckett LA et al. Age-specific incidence of Alzheimer’s disease in a community population. JAMA273(17), 1354–1359 (1995).
   PubMed Web of Science ®Google Scholar
• Narahashi T, Moriguchi S, Zhao X, Marszalec W, Yeh JZ. Mechanisms of action of cognitive enhancers on neuroreceptors. Biol. Pharm. Bull.27(11), 1701–1706 (2004).
   PubMed Web of Science ®Google Scholar
• Toda N, Tago K, Marumoto S et al. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer’s disease. Bioorg. Med. Chem.11(9), 1935–1955 (2003).
   PubMed Web of Science ®Google Scholar
• Snape MF, Misra A, Murray TK et al. A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology38(1), 181–193 (1999).
   PubMed Web of Science ®Google Scholar
• Abe Y, Aoyagi A, Hara T et al. Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer’s disease. J. Pharmacol. Sci.93(1), 95–105 (2003).
   PubMed Web of Science ®Google Scholar
• Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics5(3), 458–469 (2008).
   PubMed Web of Science ®Google Scholar
• Courtney C, Farrell D, Gray R et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet363(9427), 2105–2115 (2004).
   PubMed Web of Science ®Google Scholar
• King MV, Marsden CA, Fone KC. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol. Sci.29(9), 482–492 (2008).
   PubMed Web of Science ®Google Scholar
• Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer’s disease: maximizing benefit, managing expectations. Dement. Geriatr. Cogn. Disord.25(5), 408–422 (2008).
   PubMed Web of Science ®Google Scholar
• Bojarski L, Herms J, Kuznicki J. Calcium dysregulation in Alzheimer’s disease. Neurochem. Int.52(4–5), 621–633 (2008).
   PubMed Web of Science ®Google Scholar
• Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology53(6), 699–723 (2007).
   PubMed Web of Science ®Google Scholar
• Emre M, Mecocci P, Stender K. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer’s disease. J. Alzheimers Dis.14(2), 193–199 (2008).
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int. J. Geriatr. Psychiatry18(Suppl. 1), S23–S32 (2003).
   PubMed Web of Science ®Google Scholar
• Molinuevo JL, Llado A, Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer’s disease and other dementias. Am. J. Alzheimers Dis. Other Demen.20(2), 77–85 (2005).
   PubMedGoogle Scholar
• Sadowski M, Wisniewski T. Disease modifying approaches for Alzheimer’s pathology. Curr. Pharm. Des.13(19), 1943–1954 (2007).
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Sadowski M. Preventing β-amyloid fibrillization and deposition: β-sheet breakers and pathological chaperone inhibitors. BMC Neurosci.9(Suppl. 2), S5 (2008).
   PubMedGoogle Scholar
• Wolfe MS. Selective amyloid-β lowering agents. BMC Neurosci.9(Suppl. 2), S4 (2008).
   PubMedGoogle Scholar
• Marksteiner J, Schmidt R. Treatment strategies in Alzheimer’s disease with a focus on early pharmacological interventions. Drugs Aging21(7), 415–426 (2004).
   PubMed Web of Science ®Google Scholar
• Marcos B, Chuang TT, Gil-Bea FJ, Ramirez MJ. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br. J. Pharmacol.155(3), 434–440 (2008).
   PubMed Web of Science ®Google Scholar
• Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE. Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. Drugs67(1), 27–55 (2007).
   PubMed Web of Science ®Google Scholar
• Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol. Ther.108(3), 320–333 (2005).
   PubMed Web of Science ®Google Scholar
• Ruat M, Traiffort E, Arrang JM et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun.193(1), 268–276 (1993).
   PubMed Web of Science ®Google Scholar
• Monsma FJ Jr, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol.43(3), 320–327 (1993).
   PubMed Web of Science ®Google Scholar
• Roth BL, Craigo SC, Choudhary MS et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther.268(3), 1403–1410 (1994).
   PubMed Web of Science ®Google Scholar
• Shireman BT, Bonaventure P, Curruthers NI. Recent advances on the 5-HT5A, 5-HT6 and 5-HT7 receptors. In: Annual Reports in Medicinal Chemistry. Macor JE (Ed.). Academic Press, CA, USA 25–42 (2008).
   Google Scholar
• Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol. Ther.117(2), 207–231 (2008).
   PubMed Web of Science ®Google Scholar
• Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology41(2), 210–219 (2001).
   PubMed Web of Science ®Google Scholar
• Otano A, Frechilla D, Cobreros A et al. Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine 6 receptors in rat nucleus accumbens by antisense oligonucleotides. Neuroscience92(3), 1001–1009 (1999).
   PubMed Web of Science ®Google Scholar
• Hirst WD, Abrahamsen B, Blaney FE et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol. Pharmacol.64(6), 1295–1308 (2003).
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Liu HC, Liu TY, Wang YC, Hong CJ. Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer’s disease. Neurosci. Lett.276(2), 138–139 (1999).
   PubMed Web of Science ®Google Scholar
• Liu HC, Hong CJ, Liu CY et al. Association analysis of the 5-HT6 receptor polymorphism C267T with depression in patients with Alzheimer’s disease. Psych. Clin. Neurosci.55(4), 427–429 (2001).
   PubMed Web of Science ®Google Scholar
• Pakaski M, Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer’s disease. Neurochem. Int.53(5), 103–111 (2008).
   PubMed Web of Science ®Google Scholar
• Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer TA. Transient intraneuronal Aβ rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol.116(6), 647–655 (2008).
   PubMed Web of Science ®Google Scholar
• Christensen DZ, Bayer TA, Wirths O. Intracellular Aβ triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer’s disease. Neurobiol. Aging (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Garcia-Alloza M, Hirst WD, Chen CP, Lasheras B, Francis PT, Ramirez MJ. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer’s disease. Neuropsychopharmacology29(2), 410–416 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M et al. Cholinergic–serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia43(3), 442–449 (2005).
   PubMed Web of Science ®Google Scholar
• Gil-Bea FJ, Garcia-Alloza M, Dominguez J, Marcos B, Ramirez MJ. Evaluation of cholinergic markers in Alzheimer’s disease and in a model of cholinergic deficit. Neurosci. Lett.375(1), 37–41 (2005).
   PubMed Web of Science ®Google Scholar
• Marcos B, Garcia-Alloza M, Gil-Bea FJ et al. Involvement of an altered 5-HT6 receptor function in behavioral symptoms of Alzheimer’s disease. J. Alzheimers Dis.14(1), 43–50 (2008).
   PubMed Web of Science ®Google Scholar
• Rogers DC, Hagan JJ. 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology (Berl.)158(2), 114–119 (2001).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Alzheimer 100 – highlights in the history of Alzheimer research. J. Neural. Transm.113(11), 1603–1623 (2006).
   PubMed Web of Science ®Google Scholar
• Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol.2(9), 539–547 (2003).
   PubMed Web of Science ®Google Scholar
• Hirst WD, Stean TO, Rogers DC et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol.553(1–3), 109–119 (2006).
   PubMed Web of Science ®Google Scholar
• Woolley ML, Marsden CA, Sleight AJ, Fone KC. Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. Psychopharmacology (Berl.)170(4), 358–367 (2003).
   PubMed Web of Science ®Google Scholar
• Bentley JC, Bourson A, Boess FG et al. Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. Br. J. Pharmacol.126(7), 1537–1542 (1999).
   PubMed Web of Science ®Google Scholar
• Sleight AJ, Boess FG, Bos M, Bourson A. The putative 5-HT6 receptor: localization and function. Ann. NY Acad. Sci.861, 91–96 (1998).
   PubMed Web of Science ®Google Scholar
• Bourson A, Boess FG, Bos M, Sleight AJ. Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br. J. Pharmacol.125(7), 1562–1566 (1998).
   PubMed Web of Science ®Google Scholar
• Shirazi-Southall S, Rodriguez DE, Nomikos GG. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology26(5), 583–594 (2002).
   PubMed Web of Science ®Google Scholar
• Riemer C, Borroni E, Levet-Trafit B et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J. Med. Chem.46(7), 1273–1276 (2003).
   PubMed Web of Science ®Google Scholar
• Gerard C, Martres MP, Lefevre K et al. Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system. Brain Res.746(1–2), 207–219 (1997).
   PubMed Web of Science ®Google Scholar
• Foley AG, Murphy KJ, Hirst WD et al. The 5-HT6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology29(1), 93–100 (2004).
   PubMed Web of Science ®Google Scholar
• Marcos B, Gil-Bea FJ, Hirst WD, Garcia-Alloza M, Ramirez MJ. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur. J. Neurosci.24(5), 1299–1306 (2006).
   PubMed Web of Science ®Google Scholar
• Gerard C, el Mestikawy S, Lebrand C et al. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse23(3), 164–173 (1996).
   PubMed Web of Science ®Google Scholar
• Lindner MD, Hodges DB Jr, Hogan JB et al. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J. Pharmacol. Exp. Ther.307(2), 682–691 (2003).
   PubMed Web of Science ®Google Scholar
• Wesolowska A. The anxiolytic-like effect of the selective 5-HT6 receptor antagonist SB-399885: the impact of benzodiazepine receptors. Eur. J. Pharmacol.580(3), 355–360 (2008).
   PubMed Web of Science ®Google Scholar
• Russell MG, Dias R. Memories are made of this (perhaps): a review of serotonin 5-HT6 receptor ligands and their biological functions. Curr. Top. Med. Chem.2(6), 643–654 (2002).
   PubMedGoogle Scholar
• King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation – an effect sensitive to NMDA receptor antagonism. Neuropharmacology47(2), 195–204 (2004).
   PubMed Web of Science ®Google Scholar
• Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat. Neurosci.5(Suppl.), 1039–1042 (2002).
   PubMed Web of Science ®Google Scholar
• Schechter LE, Lin Q, Smith DL et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology33(6), 1323–1335 (2008).
   PubMed Web of Science ®Google Scholar
• Cole DC, Stock JR, Lennox WJ et al. Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT6 receptor agonist. J. Med. Chem.50(23), 5535–5538 (2007).
   PubMed Web of Science ®Google Scholar
• Foley AG, Hirst WD, Gallagher HC et al. The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology54(8), 1166–1174 (2008).
   PubMed Web of Science ®Google Scholar
• Li Z, Huang M, Prus AJ, Dai J, Meltzer HY. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res.1134(1), 70–78 (2007).
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Roth RH, Bunney BS. Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum. Neuroscience36(3), 669–676 (1990).
   PubMed Web of Science ®Google Scholar
• Glennon RA. Higher-end serotonin receptors: 5-HT5, 5-HT6, and 5-HT7. J. Med. Chem.46(14), 2795–2812 (2003).
   PubMed Web of Science ®Google Scholar
• Kolanos R, Dukat M, Roth BL, Glennon RA. Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg. Med. Chem. Lett.16(22), 5832–5835 (2006).
   PubMed Web of Science ®Google Scholar
• Doddareddy MR, Cho YS, Koh HY, Pae AN. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists. Bioorg. Med. Chem.12(15), 3977–3985 (2004).
   PubMed Web of Science ®Google Scholar
• Pullagurla MR, Westkaemper RB, Glennon RA. Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg. Med. Chem. Lett.14(17), 4569–4573 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez-Rodriguez ML, Benhamu B, de la Fuente T, Sanz A, Pardo L, Campillo M. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J. Med. Chem.48(13), 4216–4219 (2005).
   PubMed Web of Science ®Google Scholar
• Kim HJ, Doddareddy MR, Choo H et al. New serotonin 5-HT6 ligands from common feature pharmacophore hypotheses. J. Chem. Inf. Model.48(1), 197–206 (2008).
   PubMed Web of Science ®Google Scholar
• Dukat M, Mosier PD, Kolanos R, Roth BL, Glennon RA. Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J. Med. Chem.51(3), 603–611 (2008).
   PubMed Web of Science ®Google Scholar
• Young R, Bondareva T, Wesolowska A, Young S, Glennon RA. Effect of the 5-HT6 serotonin antagonist MS-245 on the actions of (-)nicotine. Pharmacol. Biochem. Behav.85(1), 170–177 (2006).
   PubMed Web of Science ®Google Scholar
• Abate C, Kolanos R, Dukat M, Setola V, Roth BL, Glennon RA. Interaction of chiral MS-245 analogs at h5-HT6 receptors. Bioorg. Med. Chem. Lett.15(15), 3510–3513 (2005).
   PubMed Web of Science ®Google Scholar
• Lee M, Rangisetty JB, Pullagurla MR et al. 1-(1-naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg. Med. Chem. Lett.15(6), 1707–1711 (2005).
   PubMed Web of Science ®Google Scholar
• Pullagurla M, Bondareva T, Young R, Glennon RA. Modulation of the stimulus effects of (+)amphetamine by the 5-HT6 antagonist MS-245. Pharmacol. Biochem. Behav.78(2), 263–268 (2004).
   PubMed Web of Science ®Google Scholar
• Chang-Fong J, Rangisetty JB, Dukat M et al. 1,2,3,4-tetrahydrocarbazoles as 5-HT6 serotonin receptor ligands. Bioorg. Med. Chem. Lett.14(8), 1961–1964 (2004).
   PubMed Web of Science ®Google Scholar
• Tsai Y, Dukat M, Slassi A et al. N1-(benzenesulfonyl)tryptamines as novel 5-HT6 antagonists. Bioorg. Med. Chem. Lett.10(20), 2295–2299 (2000).
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Van der Schyf CJ. Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer’s disease. Curr. Top. Med. Chem.8(12), 1035–1048 (2008).
   PubMed Web of Science ®Google Scholar
• Holenz J, Pauwels PJ, Diaz JL, Merce R, Codony X, Buschmann H. Medicinal chemistry strategies to 5-HT6 receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov. Today11(7–8), 283–299 (2006).
   PubMed Web of Science ®Google Scholar